SI-BONE stock barely flinched after earnings, slipping just 0.05% to US$18.44, even though the quarter put its core story into sharper focus. The company is still loss making, but Q2 showed clear operating leverage, with revenue of US$56.0m and a narrower basic loss per share of US$0.09. For a medical device stock that has already climbed more than 40% over the past three months, the flat reaction suggests investors expected progress. The key question now is whether this mix of solid top line growth and improving margins is enough to justify that move.

Love SI-BONE’s revenue traction but concerned it is still loss making? Check out our screener of list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$56.01m vs. US$48.63m (up about 15%)
• Net Loss (Q2 2026 vs. Q2 2025): US$4.09m loss vs. US$6.15m loss (loss narrowed about 33%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.09 loss per share vs. US$0.14 loss per share (per share loss improved about 37%)
• Gross Margin (Q2 2026): About 79.5% in Q2 2026 (company reported continued high gross profitability on each dollar of sales)

Prefer clear charts instead of another dense block of financial figures? See SI-BONE’s full visual breakdown, including how analysts are assessing its outlook, in the company report for SI-BONE.

SI-BONE’s Q2 Momentum Supports The Bullish Story

For investors leaning bullish on SI-BONE, Q2 directionally lines up with that view. Revenue rose about 15% year on year, and U.S. procedure volume tracked a similar pace with a strong 9% sequential lift. Gross margin held near 79.5% while operating expenses grew slower than sales, so the net loss narrowed and adjusted EBITDA margin moved into the mid single digits. Cash climbed slightly to about US$145.9m with positive operating cash flow. That mix of steady growth, better efficiency, and solid liquidity supports the view of a focused niche medtech specialist gaining traction.

Where The SI-BONE Bear Case Still Finds Support

The cautious view on SI-BONE also finds some backing in these results. The company remains loss making, and management flagged upcoming HQ and surgical capacity spending that could add near term cash variability. Guidance for about 15% to 16% full year revenue growth is framed conservatively because key drivers like new 510(k) clearances and reimbursement changes may take time to influence procedures. Management also pointed to possible average selling price pressure from interventional and trauma cases. Execution, reimbursement timing, and mix remain important swing factors for the business model.

After SI-BONE’s steady revenue progress, the bigger question is whether current losses and insider selling hint at deeper structural issues. Review our independent risk analysis for SI-BONE which shows 2 important warning signs

Stay Ahead With Simply Wall St

If SI-BONE’s mix of revenue growth, improving margins, and ongoing losses has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the story evolves. Once you decide to take a position, use the Portfolio Command Center to keep your holdings organised and focus only on the most important updates. For a broader lens on what other investors are seeing in SI-BONE and similar stocks, join the discussion in the Community. This way you can spot potential catalysts and risks early and stay a step ahead of the wider market.

Seeking Alternatives Beyond SI-BONE?

Fresh stock ideas can move quickly once momentum builds, and under-the-radar opportunities rarely stay quiet for long. Scan these curated lists before the crowd moves in and act now.

• Spot potential breakout candidates early by checking a curated mix of resilient companies in the 85 resilient stocks with low risk scores while prices still reflect yesterday’s expectations.
• Ride the wave of structural shifts in global infrastructure by reviewing carefully filtered 36 power grid technology and infrastructure stocks before interest accelerates and valuations start flying.
• Target companies with real earnings strength by scanning hand picked 68 profitable AI stocks that aren't just burning cash while they remain under the radar for now and before momentum traders get caught up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.